Lv21
120 积分 2022-06-08 加入
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)
2个月前
已完结
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
3个月前
已完结
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
4个月前
已完结
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies
5个月前
已完结
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
5个月前
已完结
Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma
6个月前
已完结
Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma
6个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
6个月前
已完结
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
6个月前
已完结
PETAL: a global view on R/R T-/NK-lymphoma treatment reality
6个月前
已关闭
皖公网安备34019202002308
